The new company was structured as a Sino-Foreign Equity Joint Venture and seeks to develop and commercialize a variety of products including pharmaceutical, functional foods, and nutraceuticals for China and the world. However SemBioSys did not transfer any intellectual property to the joint venture and Tasly terminated the agreement.
The formation of the new company was structured as a Sino-foreign partnership, with ambitions to create and sell a variety of products, including pharmaceuticals, functional foods, and nutraceuticals in China and globally. Nevertheless, SemBioSys failed to transfer any intellectual property rights to the joint venture, and Tasly ultimately decided to cancel the agreement.